laboratori corpor america hold
feb pm et
summari clinic laboratori organ offer broad rang test servic
nation network laboratori
price-to-earnings oper ep
risk assess reflect lh leadership posit
larg matur industri broad geograph servic area
client state divers balanc
payer mix note uncertainti surround
reimburs rate futur regul present
modest risk compani
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
believ larg laboratori provid
lh sustain competit advantag
due scale abil provid wide
varieti test solut lh
within diagnost complement
acquisit covanc leader faster
grow cro industri see
substanti differ capabl
reput lh larger competitor
anticip continu
market share gain lh go forward
risk recommend target price
includ signific slowdown doctor visit
pressur reimburs rate
target price
ep estim multipl premium
peer reflect improv sale growth
outlook expect slight margin
expans benefici mix shift
see sale rise
diagnost segment grow
believ lh well posit
volum increas market share gain within
diagnost cdd segment provid
increment opportun organ growth
addit see lh benefit
insur patient due healthcar reform
expect revenu per requisit benefit
esoter test continu exit
center medicar medicaid servic
reimburs rate clinic laboratori
test clinic lab fee schedul
clf half total code receiv
maximum rate cut
protect access medicar act
test price cut
see slight oper margin expans
result launchpad initi
continu synergi off-set guid
paml reduct long-term margin
growth may come higher esoter test
volum addit acquisit see
ep
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
laboratori corpor america hold
senior vice presid
offic presid
chief offic
laboratori director
corpor overview laboratori corpor america second-largest independ clinic
laboratori clinic laboratori test use medic profession routin test patient diagnosi
monitor treatment diseas decemb lh roughli primari test
facil servic site consist branch patient servic center stat
laboratori abil perform certain routin test quickli report result
physician immedi compani laboratori servic involv test bodili fluid
human tissu lh offer differ test consist routin test specialti
nich test esoter frequent administ routin test includ blood chemistri analys
urinalysi blood cell count pap test hiv test microbiolog cultur procedur well alcohol
substanc abus test compani esoter test includ test infecti diseas
allergi diagnost genet ident oncolog averag specimen
process daili decemb routin test result gener avail within hour
lh provid test servic broad rang health care provid includ independ physician
hospit hmo manag care group well government institut
singl client account net sale test servic bill parti
physician author person order test payor direct patient
includ insur compani manag care organ august lh acquir medtox
scientif million decemb lh acquir orchid cellmark part agreement
ftc lh divest orchid govern patern busi june lh acquir clearston
central lab global provid central laboratori servic late stage clinic trial april lh
acquir westcliff lab ftc lost court rule tri block deal decemb lh
acquir genzym genet unit genzym corpor million august lh acquir
monogram bioscienc provid molecular diagnost test februari lh acquir nwt inc
provid drug abus test juli lh acquir dsi lab expand oper southwest
florida may compani acquir esoterix inc provid specialti refer test
februari lh bought us lab locat irvin ca
corpor strategi februari lh acquir covanc cvd billion consist
cash lh share cvd share cvd lead contract research organ cro
provid outsourc drug develop servic world-wide pharmaceut biotech medic
devic industri cro industri grow around annual low-single-digit growth
see clinic laboratori industri histor major compon growth clinic lab
industri lh acquir laboratori high fixed-cost compon oper
laboratori make acquir consolid lab attract avenu growth enabl
expans oper margin view howev think pauciti sizabl clinic lab
remain acquir therefor think lh must focu growth area one lh primari
growth strategi continu expand esoter test capabl gener
profit routin test compon strategi partner enter variou
agreement diagnost compani develop esoter diagnost test compani esoter
lab includ center molecular biolog patholog locat research triangl nc nation
genet institut lo angel ca viro-m lab minneapoli mn dianon system stratford
ct septemb lh acquir sequenom inc market leader non-invas prenat test
women health reproduct genet million
competit landscap clinic lab industri estim gener billion annual
revenu highli competit thousand independ clinic lab physician offic lab
hospital-bas lab lh second-largest provid lab servic enjoy leverag
competitor compani main competitor publicly-trad largest clinic lab
provid smaller competitor includ bio-refer laboratori medtox scientif
signific consolid past decad major publicli trade lab acquir
primarili lh
financi trend sale rose billion billion repres compound
annual growth rate compound-annual-growth-rate think sale driven organ growth acquisit
exclus nation laboratori contract unitedhealthcar effect januari
compani recent extend deal end think contract provid
billion increment sale life deal adjust ep increas
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
lh under-valued
bullish sinc novemb technic indic
lh bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
fundament outlook health care
servic sub-industri next month
neutral think servic includ
rehabilit clinic laboratori
dialysi continu benefit
favor demograph partli offset
increas pressur reduc govern
spend rais possibl medicar
reimburs rate cut possibl
repeal elimin medicaid
expans trump administr
becom neutral dialysi group
view favor patient demograph
off-set reimburs rate pressur
center medicar medicaid servic look
cut expens expect provid see
higher treatment margin due lower drug
cost util think provid
still reliant maintain
commerci base rate much higher
offer medicar think
age popul increas focu
prevent care benefit clinic lab
think increas test per requisit
esoter test lead low singl
remain posit pharmaci benefit manag
pbm see pbm benefit
billion dollar brand drug slate
lose patent protect come year
expect republican administr
continu effort repeal
servic sub-industri larg exposur
medicaid clientel could advers
uncompens care rate could rise
hospit facil would lead
lower profit lower demand health
care servic senat fail multipl
base index
five-year market price perform feb
time past month gather
suffici number vote pass variou
repeal replac bill believ
republican revisit futur
indic shift
attent tax reform futur potenti
repeal bill would take effect
opinion give sub-industri time
adjust mitig impact new
year-to-d septemb
increas composit
 health servic
fell vs increas
note sector sub-industri inform base
past perform indic futur perform
reli upon
laboratori corpor america
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
expect sale growth driven recoveri drug develop
volum growth diagnost /k snyder
et cfra maintain buy opinion share laboratori
corpor america lh keep target price
ep estim multipl slight discount
peer reflect slower revenu growth outlook cut
ep estim lh report
oper ep vs consensu sale
increas growth diagnost partial off-set
declin drug develop due slower revenu convers backlog
expect sale growth driven diagnost higher volum
price acquisit /k snyder
laboratori corpor america hold announc gari huff
promot ceo labcorp diagnost one compani two
primari busi segment effect immedi huff recent serv
head labcorp diagnost hospit health system group
member labcorp execut committe report king
laboratori corpor america lh maintain
target ep estim multipl
line peer reflect stabl sale growth outlook expect
modest margin expans benefici mix shift reduc cost trim
ep estim set
lh report oper ep vs capit
iq consensu sale increas growth diagnost see
sale growth aid acquisit note lh re-initi
stock repurchas program purchas /k snyder
laboratori corpor america lh accord
unconfirm report reuter lh talk acquir
product develop llc privat contract research accord
report deal could high billion includ debt note
certainti deal reach potenti agreement
might come sever week see unconfirm report
neg lh deal would largest ever believ lh still
work integr covanc contract research compani purchas
billion /k snyder
analyst research note compani news
corpor america lh keep target price
ep estim slight premium three-year forward
averag price-to-earnings reflect improv sale growth outlook rais
ep estim set lh report
oper ep vs consensu sale
increas growth drug develop segment driven
chiltern acquisit expect sale growth driven
acquisit volum growth diagnost partial off-set price
corpor america lh rais target
ep estim premium peer reflect increas
confid growth covanc acquisit rais
ep estim lh report
oper ep vs consensu sale
increas organ growth acquisit
diagnost covanc drug develop cdd segment perform well
respect despit headwind hurrican expect
revenu growth /keith snyder danni yang
corpor america lh center medicar
clinic laboratori test clinic lab fee schedul clf
accord propos payment lab test would decreas
major test code receiv maximum reduct lh issu
statement question valid data use calcul propos
rate see slight neg lh given low exposur
medicar reimburs note compani like challeng propos
rate court /keith snyder
labcorp announc dr brian caveney nation recogn
health-polici expert current serv chief medic offic
cross shield north carolina cross nc fill newli
creat role enterprise-wid chief medic offic labcorp effect
sept caveney report david king chairman ceo labcorp
newli creat role caveney broad respons
labcorp medic scientif strategi includ serv primari medic
repres compani extern defin global standard medic
scientif activ across labcorp diagnost drug develop
busi enhanc cultur medic scientif excel
et cfra maintain buy opinion share laboratori
corpor america lh lh announc sign
definit agreement acquir chiltern specialti contract research
organ billion cash fund bank financ bond
transact subject customari close condit regulatori
approv expect close view deal
posit chiltern expand lh presenc fast-grow
oncolog therapeut area key focu pharma
industri addit chiltern focu small mid-siz client
accret lh larger biopharma client base /k snyder
et cfra maintain buy opinion share laboratori
corpor america lh rais target
ep estim premium peer reflect
improv sale growth outlook trim ep
estim lh report oper
ep vs consensu sale increas
growth diagnost partial off-set declin drug
develop due cancel two larg clinic trial late last year
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
fiscal year analyst estim lh earn
usd fiscal year analyst estim
lh earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
